Abstract

IBDoc Canadian User Performance Evaluation

Moore AC1, Huang VW2, Bourdages R3, Fedorak RN4, Reinhard C5, Leung Y1, Bressler B1, Rosenfeld G1. Inflamm Bowel Dis. 2018 Dec 8. doi: 10.1093/ibd/izy357. [Epub ahead of print]
 
     

Author information

1 Department of Gastroenterology, University of British Columbia, Vancouver, Canada.

2 Division of Gastroenterology, University of Toronto, Toronto, Canada.

3 CSSS Alphonse-Desjardins, Lévis, Quebec, Canada.

4 Division of Gastroenterology, University of Alberta, Edmonton, Canada.

5 BÜHLMANN Laboratories AG, Switzerland.

Abstract

BACKGROUND: Fecal calprotectin (FC) is a stool biomarker that has been shown to be sensitive and specific for mucosal inflammation in patients with inflammatory bowel disease (IBD). The test is limited by the requirement for patients to collect and return stool samples. A home-based FC test may improve test adherence. The aim of this study is to evaluate the usability of the IBDoc, a home-based FC measuring test, and to determine the accuracy of results compared with traditional lab-based ELISA values.

METHODS: Patients were prospectively enrolled from 3 tertiary sites across Canada between May and August 2017. Patients completed a questionnaire establishing ease-of-use of the IBDoc. Patients completed a FC measurement using the IBDoc, and results were compared with an ELISA-determined FC measurement on the same stool sample.

RESULTS: Sixty-one participants were enrolled in the study (29 CD, 32 UC). Seventy-nine percent of patients (48 of 61) agreed that the IBDoc was easy to use, with 85% (52 of 61) of patients strongly agreeing that they were willing use the home kit in the future. The IBDoc and ELISA measurement comparison showed an 88% agreement across all values. There were no false positives or negatives using qualitative comparison.

CONCLUSIONS: The home-based IBDoc FC measuring test is acceptable to patients and correlates extremely well with the standard ELISA-determined FC value. The IBDoc enables clinicians to more easily adopt a treat-to-target approach, improve long-term outcomes, and patients' quality of life with IBD. This study is registered at ClinicalTrials.gov, number NCT03408249.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.